Liquidia Corp LQDA
Institutional shares held
54 Million
6.33M
calls
7.87M
puts
Total value of holdings
$1.54B
$181M
calls
$225M
puts
Market Cap
$1.84B
64,362,300
Shares Out.
Institutional ownership
83.97%
# of Institutions
240
We take great care to ensure that the data presented and summarized in this overview for Liquidia Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LQDA
View all-
Farallon Capital Management LLC San Francisco, CA8.57MShares$245 Million0.85% of portfolio
-
Black Rock Inc. New York, NY4.24MShares$121 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.96MShares$113 Million0.0% of portfolio
-
Findell Capital Management LLC New York, NY2.83MShares$80.9 Million25.4% of portfolio
-
Goldman Sachs Group Inc New York, NY2.78MShares$79.5 Million0.01% of portfolio
-
Opaleye Management Inc. Boston, MA2.62MShares$74.7 Million10.0% of portfolio
-
State Street Corp Boston, MA1.91MShares$54.7 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.71MShares$48.9 Million4.4% of portfolio
-
Caprock Group, Inc.1.63MShares$46.6 Million0.92% of portfolio
-
Geode Capital Management, LLC Boston, MA1.61MShares$45.9 Million0.0% of portfolio
Latest Institutional Activity in LQDA
Top Purchases
Top Sells
About LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Insider Transactions at LQDA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 16
2026
|
Dana Boyle Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,728
+11.62%
|
-
|
|
Jan 16
2026
|
Jason Adair Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,683
+11.56%
|
-
|
|
Jan 16
2026
|
Sarah Krepp Chief Human Resource Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,728
+12.61%
|
-
|
|
Jan 16
2026
|
Sanjeev Khindri Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,274
+32.47%
|
-
|
|
Jan 16
2026
|
Michael Kaseta CFO and COO |
BUY
Grant, award, or other acquisition
|
Direct |
59,320
+12.63%
|
-
|
|
Jan 16
2026
|
Roger Jeffs Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
115,344
+9.1%
|
-
|
|
Jan 16
2026
|
Russell Schundler General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
32,955
+5.11%
|
-
|
|
Jan 16
2026
|
Rajeev Saggar Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,955
+13.57%
|
-
|
|
Jan 16
2026
|
Scott Moomaw Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,955
+14.95%
|
-
|
|
Jan 12
2026
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
36,932
-9.52%
|
$1,366,484
$37.43 P/Share
|
|
Jan 12
2026
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
20,533
-11.73%
|
$759,721
$37.43 P/Share
|
|
Jan 12
2026
|
Sarah Krepp Chief Human Resource Officer |
SELL
Open market or private sale
|
Direct |
13,165
-8.55%
|
$487,105
$37.43 P/Share
|
|
Jan 12
2026
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,142
-10.68%
|
$782,254
$37.43 P/Share
|
|
Jan 12
2026
|
Dana Boyle Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
11,047
-6.59%
|
$408,739
$37.43 P/Share
|
|
Jan 12
2026
|
Roger Jeffs Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
66,610
-6.03%
|
$2,464,570
$37.43 P/Share
|
|
Jan 12
2026
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
27,289
-4.5%
|
$1,009,693
$37.43 P/Share
|
|
Jan 12
2026
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
13,548
-6.85%
|
$501,276
$37.43 P/Share
|
|
Jan 09
2026
|
Michael Kaseta CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,028
+4.19%
|
-
|
|
Jan 09
2026
|
Scott Moomaw Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,541
+5.5%
|
-
|
|
Jan 09
2026
|
Sarah Krepp Chief Human Resource Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,716
+7.63%
|
-
|
Last 12 Months Summary
Buy / Acquisition
1.17M
Shares
From
26
Insiders
| Grant, award, or other acquisition | 580K shares |
|---|---|
| Exercise of conversion of derivative security | 591K shares |
Sell / Disposition
1.51M
Shares
From
11
Insiders
| Open market or private sale | 1.51M shares |
|---|